The group’s principle activity is to develop therapeutic and vaccine technologies to reduce morbidity and mortality caused by viral diseases. The group’s technologies include Antiviral Immune Modulating therapy, thermal stabilizers, genetic adjuvants, and transition state vaccines. The group operates from United States.
